Literature DB >> 24928698

Acute kidney injury associated with high nephrotoxic medication exposure leads to chronic kidney disease after 6 months.

Shina Menon1, Eric S Kirkendall2, Hovi Nguyen3, Stuart L Goldstein3.   

Abstract

OBJECTIVE: To assess the development of chronic kidney disease (CKD) after high nephrotoxic medication exposure-associated acute kidney injury (NTMx-AKI) in hospitalized children. STUDY
DESIGN: We performed a retrospective cohort study of children exposed to an aminoglycoside for ≥3 days or ≥3 nephrotoxic medications simultaneously for the development of CKD at 6 months. Follow-up data >6 months after acute kidney injury (AKI) were retrieved from electronic health records. Outcomes in children with NTMx-AKI were compared with patients of same age and primary service distribution who were exposed to nephrotoxic medications but did not develop AKI (controls).
RESULTS: One hundred patients with NTMx-AKI were assessed (mean age of 9.3 ± 6.9 years). Commonly involved services were bone marrow transplantation/oncology (59%), liver transplantation (13%), and pulmonary (13%). Pre-AKI estimated glomerular filtration rate (eGFR) was 119 ± 14.5 mL/min/1.73 m(2) (range 90-150 mL/min/1.73 m(2)). Mean discharge eGFR was 105.1 ± 27.1 mL/min/1.73 m(2). At 6 months after NTMx-AKI, eGFR (n = 77) was 113.8 ± 30.6 mL/min/1.73 m(2). Sixteen (20.7%) had eGFR of 60-90, 2 (2.6%) had eGFR <60, and 9 (11.6%) had eGFR >150 mL/min/1.73 m(2) (hyperfiltration). Twenty-four (68.5%) of 35 patients who were assessed for proteinuria had a urine protein-to-creatinine ratio >0.3 mg/mg, and 29 (37.6%) had hypertension. Twenty-six (33.7%) patients had CKD (proteinuria or eGFR <60 mL/min/1.73 m(2)). An additional 28 (36.3%) were considered to be at risk for CKD with hypertension, eGFR between 60 and 90 mL/min/1.73 m(2), or eGFR >150 mL/min/1.73 m(2). CKD, hypertension, and proteinuria were more common in the AKI cohort than in controls.
CONCLUSIONS: Six months after NTMx-AKI, 70% of patients had evidence of residual kidney damage (reduced eGFR, hyperfiltration, proteinuria, or hypertension). Few underwent a complete evaluation for CKD. With studies showing an association between AKI and CKD, we suggest systematic comprehensive follow-up in children after NTMx-AKI.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24928698     DOI: 10.1016/j.jpeds.2014.04.058

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  60 in total

1.  Baby NINJA (Nephrotoxic Injury Negated by Just-in-Time Action): Reduction of Nephrotoxic Medication-Associated Acute Kidney Injury in the Neonatal Intensive Care Unit.

Authors:  Christine Stoops; Sadie Stone; Emily Evans; Lynn Dill; Traci Henderson; Russell Griffin; Stuart L Goldstein; Carl Coghill; David J Askenazi
Journal:  J Pediatr       Date:  2019-12       Impact factor: 4.406

2.  Acute Kidney Injury Incidence in Noncritically Ill Hospitalized Children, Adolescents, and Young Adults: A Retrospective Observational Study.

Authors:  Tracy L McGregor; Deborah P Jones; Li Wang; Ioana Danciu; Brian C Bridges; Geoffrey M Fleming; Jana Shirey-Rice; Lixin Chen; Daniel W Byrne; Sara L Van Driest
Journal:  Am J Kidney Dis       Date:  2015-08-28       Impact factor: 8.860

3.  Acute kidney injury in critically ill children and 5-year hypertension.

Authors:  Erin Hessey; Sylvie Perreault; Louise Roy; Marc Dorais; Susan Samuel; Véronique Phan; Jean-Philippe Lafrance; Michael Zappitelli
Journal:  Pediatr Nephrol       Date:  2020-03-11       Impact factor: 3.714

Review 4.  Drug-associated acute kidney injury: who's at risk?

Authors:  Emily L Joyce; Sandra L Kane-Gill; Dana Y Fuhrman; John A Kellum
Journal:  Pediatr Nephrol       Date:  2016-06-23       Impact factor: 3.714

5.  Increased Vancomycin Exposure and Nephrotoxicity in Children: Therapeutic Does Not Mean Safe.

Authors:  Kevin J Downes; Stuart L Goldstein; Alexander A Vinks
Journal:  J Pediatric Infect Dis Soc       Date:  2014-12-29       Impact factor: 3.164

6.  Serum cystatin C for acute kidney injury evaluation in children treated with aminoglycosides.

Authors:  Lorraine Lau; Zubaida Al-Ismaili; Maya Harel-Sterling; Michael Pizzi; Jillian S Caldwell; Melissa Piccioni; Larry C Lands; Theresa Mottes; Prasad Devarajan; Stuart L Goldstein; Michael R Bennett; Michael Zappitelli
Journal:  Pediatr Nephrol       Date:  2016-10-14       Impact factor: 3.714

Review 7.  Preterm birth and neonatal acute kidney injury: implications on adolescent and adult outcomes.

Authors:  Matthew W Harer; Jennifer R Charlton; Trent E Tipple; Kimberly J Reidy
Journal:  J Perinatol       Date:  2020-04-10       Impact factor: 2.521

8.  Risk factors for acute kidney injury during aminoglycoside therapy in patients with cystic fibrosis.

Authors:  Kevin J Downes; Neha R Patil; Marepalli B Rao; Rajesh Koralkar; William T Harris; John P Clancy; Stuart L Goldstein; David J Askenazi
Journal:  Pediatr Nephrol       Date:  2015-04-26       Impact factor: 3.714

9.  Identifying High-Risk Medications Associated with Acute Kidney Injury in Critically Ill Patients: A Pharmacoepidemiologic Evaluation.

Authors:  Morgan B Slater; Andrea Gruneir; Paula A Rochon; Andrew W Howard; Gideon Koren; Christopher S Parshuram
Journal:  Paediatr Drugs       Date:  2017-02       Impact factor: 3.022

Review 10.  Pediatric acute kidney injury and the subsequent risk for chronic kidney disease: is there cause for alarm?

Authors:  Vaka K Sigurjonsdottir; Swasti Chaturvedi; Cherry Mammen; Scott M Sutherland
Journal:  Pediatr Nephrol       Date:  2018-01-26       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.